NEW BRUNSWICK, N.J.,
Oct. 4, 2015 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced the
completion of the divestiture of its Cordis business to Cardinal
Health for an approximate value of $2
billion, subject to customary adjustments.
The Cordis business is a global leader in the development and
manufacture of interventional vascular technology and generated net
revenues of approximately $780
million in 2014.
Johnson & Johnson remains dedicated to combating
cardiovascular disease through its electrophysiology business,
Biosense Webster, in the Medical Devices segment, and its leading
cardiovascular medicine, XARELTO®, in the Pharmaceutical
segment.
About Cordis
Cordis is a leader in the development and manufacture of
interventional vascular technology, partnering with experts
worldwide to treat millions of patients who suffer from vascular
disease. The business has operations in more than 50 countries,
with an extensive research and development network and a global
commercial footprint.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites
the people of Johnson & Johnson. We embrace research and
science - bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
127,000 employees at more than 265 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-announces-completion-of-cordis-divestiture-to-cardinal-health-300153808.html
SOURCE Johnson & Johnson